Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

CABA - Cabaletta Bio, Inc. So'nggi Yangiliklar | Finranks

Home

CABA

(CABA)

NMS – Real vaqt narxi. Valyuta: USD

2.68

-0.14 (-4.96%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

2.68

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 7:35 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option

Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know

Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know

Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference

Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference

PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 11:10 a.m. ET in Boston, MA.

Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 9:30 a.m. ET in New York, NY.

What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now?

What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now?

Does Cabaletta Bio, Inc. (CABA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Cabaletta Bio: Do You Buy With The Insiders?

Cabaletta Bio: Do You Buy With The Insiders?

Cabaletta Bio continues to advance its engineered cell therapy pipeline targeting autoimmune diseases, maintaining cautious optimism. Recent insider share purchases have apparently bolstered confidence in CABA's prospects following key data releases since October. At Q3 2025, CABA reported $60.2 million in cash and $99.7 million in short-term investments, supporting ongoing development.

Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year?

Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year?

Here is how Cabaletta Bio, Inc. (CABA) and Celcuity, Inc. (CELC) have performed compared to their sector so far this year.

Videolar

No Data

There is no data to display